Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,898 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prevalence of disease-causing genes in Japanese patients with BRCA1/2-wildtype hereditary breast and ovarian cancer syndrome.
Kaneyasu T, Mori S, Yamauchi H, Ohsumi S, Ohno S, Aoki D, Baba S, Kawano J, Miki Y, Matsumoto N, Nagasaki M, Yoshida R, Akashi-Tanaka S, Iwase T, Kitagawa D, Masuda K, Hirasawa A, Arai M, Takei J, Ide Y, Gotoh O, Yaguchi N, Nishi M, Kaneko K, Matsuyama Y, Okawa M, Suzuki M, Nezu A, Yokoyama S, Amino S, Inuzuka M, Noda T, Nakamura S. Kaneyasu T, et al. Among authors: ohno s. NPJ Breast Cancer. 2020 Jun 12;6:25. doi: 10.1038/s41523-020-0163-1. eCollection 2020. NPJ Breast Cancer. 2020. PMID: 32566746 Free PMC article.
Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population.
Toi M, Iwata H, Yamanaka T, Masuda N, Ohno S, Nakamura S, Nakayama T, Kashiwaba M, Kamigaki S, Kuroi K; Japan Breast Cancer Research Group-Translational Research Group. Toi M, et al. Among authors: ohno s. Cancer. 2010 Jul 1;116(13):3112-8. doi: 10.1002/cncr.25206. Cancer. 2010. PMID: 20564629 Free article.
Ipsilateral breast tumor recurrence (IBTR) in patients with operable breast cancer who undergo breast-conserving treatment after receiving neoadjuvant chemotherapy: risk factors of IBTR and validation of the MD Anderson Prognostic Index.
Ishitobi M, Ohsumi S, Inaji H, Ohno S, Shigematsu H, Akiyama F, Iwase T, Akashi-Tanaka S, Sato N, Takahashi K, Oura S. Ishitobi M, et al. Among authors: ohno s. Cancer. 2012 Sep 15;118(18):4385-93. doi: 10.1002/cncr.27377. Epub 2012 Jan 17. Cancer. 2012. PMID: 22252882 Free article.
Subjective and objective assessment of edema during adjuvant chemotherapy for breast cancer using taxane-containing regimens in a randomized controlled trial: The National Surgical Adjuvant Study of Breast Cancer 02.
Ohsumi S, Shimozuma K, Ohashi Y, Takeuchi A, Suemasu K, Kuranami M, Ohno S, Watanabe T. Ohsumi S, et al. Among authors: ohno s. Oncology. 2012;82(3):131-8. doi: 10.1159/000336480. Epub 2012 Mar 15. Oncology. 2012. PMID: 22433221 Clinical Trial.
A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer.
Iwata H, Masuda N, Ohno S, Rai Y, Sato Y, Ohsumi S, Hashigaki S, Nishizawa Y, Hiraoka M, Morimoto T, Sasano H, Saeki T, Noguchi S. Iwata H, et al. Among authors: ohno s. Breast Cancer Res Treat. 2013 Jun;139(2):441-51. doi: 10.1007/s10549-013-2573-3. Epub 2013 May 30. Breast Cancer Res Treat. 2013. PMID: 23715630 Free PMC article. Clinical Trial.
For choosing axillary treatment, and adjuvant hormonal treatment.
Toi M, Ohno S, Saeki T, Nakamura S, Thürlimann B. Toi M, et al. Among authors: ohno s. Breast Cancer. 2016 Mar;23(2):167-9. doi: 10.1007/s12282-015-0662-3. Epub 2015 Dec 21. Breast Cancer. 2016. PMID: 26689708 No abstract available.
2,898 results